Skip to main content
Clinical Trials/EUCTR2018-004696-12-IT
EUCTR2018-004696-12-IT
Active, not recruiting
Phase 1

Clinical, Instrumental and Histological evaluation of the combined use of Onabotulinumtoxin A and hyaluronic acid fillers in patients with facial paralysis - Onabotulinumtoxin A and hyaluronic acid fillers in the treatment of facial paralysis

AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA0 sites70 target enrollmentMay 24, 2021

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
hemifacial paralysis (3 to 6 of the House-Brackmann scale)
Sponsor
AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
Enrollment
70
Status
Active, not recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 24, 2021
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • \-Adult patients (18\-65\) with hemifacial paralysis from 3 to 6 on the House\-Brackmann scale, never treated with HA and BTX injection will be included in the study.
  • \-Signed informed consent.
  • \-Women of childbearing potential will only be included in the study if uptaking the following highly effective birth control measures: Women of childbearing potential will only be included in the study if uptaking the following highly effective birth control measures: \- Combined hormonal contraception associated with inhibition of ovulation (Oral, Transdermal, Intravaginal), \- Progesteron\-only hormonal contraception associated with inhibition of ovulation (Oral, Injectable, Implantable), \- Intrauterine devices, \- Intrauterine hormone\-releasing system, \- Bilateral tubal occlusion, \- vasectomized partner, \- Sexual abstinence
  • \- Patients will be included after a negative highly sensitive pregnancy test (blood test)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 70
  • F.1\.3 Elderly (\>\=65 years) no
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • \-Hypersensitivity to any component of the products used
  • \-Diabetes, systemic diseases, coronary artery disease, acute\-chronic hepatitis C, autoimmune diseases and / or other diseases involving poor general health, clotting problem. Peripheric neuro\-muscolars disorders, amyotrophic lateral sclerosis (ALS).
  • \-Pregnant or lactating
  • \-Patients \<18 years and \>65 years old

Outcomes

Primary Outcomes

Not specified

Similar Trials